Sign in

CIK 0001806310

  • Non-accelerated filer
  • Smaller reporting company

Taysha Gene Therapies, Inc.

Sign in to watch
Ticker
TSHA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
843199512
Phone
+1 214-612-0000
Business address
3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2023-07-13 Session R.A. II 10% owner Sale −5,344 $0.70 $4K 8,871,747
2023-07-12 Session R.A. II 10% owner Sale −80,528 $0.71 $57K 8,877,091
2023-06-23 Session R.A. II 10% owner Sale −18,100 $0.70 $13K 8,957,619
2023-06-22 Session R.A. II 10% owner Sale −10,508 $0.70 $7K 8,975,719
2023-06-21 Session R.A. II 10% owner Sale −138,962 $0.70 $98K 8,986,227
2023-06-20 Session R.A. II 10% owner Sale −295,653 $0.71 $210K 9,125,189
2023-03-06 Session R.A. II 10% owner Other acquisition +251,296 9,420,842
2023-03-06 Session R.A. II 10% owner Returned to the company · Employee Stock Option (right to buy) −199,500 0
2022-11-10 Session R.A. II Director Grant or award · Employee Stock Option (right to buy) +199,500 199,500
2022-02-23 Session R.A. II President and CEO Grant or award · Employee Stock Option (right to buy) +217,850 217,850
2021-11-23 Session R.A. II President and CEO Purchase +16,510 $12.12 $200K 9,164,912
2021-11-23 Session R.A. II President and CEO Purchase +26,008 $12.65 $329K 9,190,920
2021-01-19 Session R.A. II President and CEO Grant or award · Stock Option (Right to Buy) +199,700 199,700

Page 1 of 1 · 13 trades